Clinical Trial

Correlation Between Serum Uric Acid, Serum Homocysteine Level and Interleukin- 17 in Lupus Nephritis Patients

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated June 12, 2025 (before its estimated February 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
Systemic lupus erythematosus (SLE) is a chronic inflammatory multisystem autoimmune disease characterized by pathogenic autoantibodies production against nuclear structures . SLE affecting mainly women of childbearing age and is characterized by unpredictable flares and remissions. Disease severity varied from a mild episodic disorder to a rapidly progressive life-threatening illness. The kidney is the most commonly involved visceral organ in SLE. Therefore, identifying new noninvasive biomarkers of LN severity and outcome is mandatory. IL-17 is a potent pro-infammatory cytokine that amplifes T-cell activation and stimulates fibroblast cells, endothelial, and epithelial cells to produce several pro-infammatory mediators, including IL-1β, IL-6, and TNF-α. IL-17 receptor signaling enhances the expression of multiple pro-infammatory mediators. Hence, IL-17 enhances the production of neutrophil-attracting chemokines
Trial Details
NCT Number NCT07017868
Lead Sponsor Sohag University
Conditions Homocysteine Level and Interleukin- 17 in Lupus Nephritis Patients
Enrollment 120 participants
Start Date 2025-01-01
Primary Completion 2026-02-01 (estimated)
Study Completion 2026-04-01 (estimated)
Updated on ClinicalTrials.gov 2025-06-12